Persephone Biosciences to Present at Chardan’s 4th Annual Metagenomics and Microbiome Medicines Summit

SAN DIEGO–(BUSINESS WIRE)–Persephone Biosciences Inc., a biotechnology company aiming to develop better treatment outcomes and improve disease prevention through a greater understanding of the microbiome, today announced that the company will present and host 1×1 meetings with investors at Chardan’s 4^th Annual Metagenomics and Microbiome Medicines Summit.

• The company’s presentation will take place virtually on March 1, 2022, at 4:00 p.m. ET.
• Dr. Stephanie Culler, Persephone Biosciences’ co-founder and CEO, will also participate in the panel titled, “Great Debate – Is the term ‘Microbiome’ Drug Development Now Passé?” at 3:15 p.m. ET.

About Persephone Biosciences

Persephone aims to develop better treatment outcomes and improve disease prevention through a greater understanding of the microbiome. Persephone’s technology platform is based on diverse and inclusive, population-scale, observational clinical trials in conjunction with advanced multi-omics analyses and machine learning with the aim to probe the complex interaction between microbes and the immune system. Persephone develops precision immunotherapies utilizing synthetic biology and companion diagnostics for unmet needs and more equitable treatment outcomes.

For more information, visit www.persephonebiosciences.com

Contacts

Dr. Stephanie Culler

CEO and Co-founder

Persephone Biosciences, Inc.

[email protected]

Laurence Watts

Managing Director

Gilmartin Group, LLC.

[email protected]

Media Contacts:
Evan Wicker, Ph.D.

Russo Partners, LLC

[email protected]
212-845-4235

Olipriya Das, Ph.D.

Russo Partners, LLC

[email protected]
646-942-5588